Targeting mitotic control, either by selective inhibition of CDK1 or aberrant activation of CDK1 via Wee1 inhibition, has been successful in increasing the efficacy of PTX in breast and ovarian cancers [41, 42]. The gene discussed is CDK1; the disease is ovarian carcinoma.